Claim 1 (currently amended): ~~Combination~~ A combination comprising a dipeptidylpeptidase-IV (DPP-IV) inhibitor which is a *N*-(*N'*-substituted glycyl)-2-cyanopyrrolidine of formula (I)



(I)

wherein R is:

a) $R_1R_{1a}N(CH_2)_m$-,
wherein
R_1 is a pyridinyl or pyrimidinyl moiety optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy, halogen, trifluoromethyl, cyano or nitro; or phenyl optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy or halogen;
R_{1a} is hydrogen or (C_{1-8})alkyl; and
m is 2 or 3;

b) (C_{3-12})Cycloalkyl optionally mono-substituted in the 1-position with (C_{1-3})hydroxyalkyl;

c) $R_2(CH_2)_n$-,
wherein either
R_2 is phenyl optionally mono- or independently di- or, independently, tri-substituted with lower alkyl, lower alkoxy, halogen or phenylthio optionally mono-substituted in the phenyl ring with hydroxymethyl; or is (C_{1-8})alkyl; a [3.1.1]bicyclic carbocyclic moiety optionally mono- or pluri-substituted with (C_{1-8})alkyl; a pyridinyl or naphthyl moiety optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy or halogen; cyclohexene; or adamantyl; and
n is 1-3; or
R_2 is phenoxy optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy or halogen; and
n is 2 or 3;

d) $(R_3)_2CH(CH_2)_2$-, wherein each R_3, independently, is phenyl optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy or halogen;

e) $R_4(CH_2)_p$-,
wherein
R_4 is 2-oxopyrrolidinyl or (C_{2-4})alkoxy; and
p is 2-4;

f) isopropyl optionally mono-substituted in 1-position with (C_{1-3})hydroxyalkyl;

g) R_5, wherein R_5 is indanyl, a pyrrolidinyl or piperidinyl moiety optionally substituted with benzyl, a [2.2.1]- or [3.1.1]bicyclic carbocyclic moiety optionally mono- or pluri-substituted with (C_{1-8})alkyl, adamantyl or (C_{1-8})alkyl optionally mono- or, independently, pluri-substituted with hydroxy, hydroxymethyl or phenyl optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy or halogen;

h) a substituted adamantyl

in free form or in acid addition salt form;

and at least one peroxisome proflierator-activated receptor □ (PPAR□) in free form or in acid addition salt form.

Claim 2 (original): A pharmaceutical composition comprising a DPP-IV inhibitor which is a *N*-(*N'*-substituted glycyl)-2-cyanopyrrolidine of formula (I)



(I)

wherein R is:

a) $R_1R_{1a}N(CH_2)_m$-,
wherein
R_1 is a pyridinyl or pyrimidinyl moiety optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy, halogen, trifluoromethyl, cyano or nitro; or phenyl optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy or halogen;
R_{1a} is hydrogen or (C_{1-8})alkyl; and
m is 2 or 3;

b) (C_{3-12})Cycloalkyl optionally mono-substituted in the 1-position with (C_{1-3})hydroxyalkyl;

c) $R_2(CH_2)_n$-,
wherein either
R_2 is phenyl optionally mono- or independently di- or, independently, tri-substituted with lower alkyl, lower alkoxy, halogen or phenylthio optionally mono-substituted in the phenyl ring with hydroxymethyl; or is (C_{1-8})alkyl; a [3.1.1]bicyclic carbocyclic moiety optionally mono- or pluri-substituted with (C_{1-8})alkyl; a pyridinyl or naphthyl moiety optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy or halogen; cyclohexene; or adamantyl; and
n is 1-3; or
R_2 is phenoxy optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy or halogen; and

n is 2 or 3;

d) $(R_3)_2CH(CH_2)_2$-, wherein each R_3, independently, is phenyl optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy or halogen;

e) $R_4(CH_2)_p$-,
wherein
R_4 is 2-oxopyrrolidinyl or (C_{2-4})alkoxy; and
p is 2-4;

f) isopropyl optionally mono-substituted in 1-position with (C_{1-3})hydroxyalkyl;

g) R_5, wherein R_5 is indanyl, a pyrrolidinyl or piperidinyl moiety optionally substituted with benzyl, a [2.2.1]- or [3.1.1]bicyclic carbocyclic moiety optionally mono- or pluri-substituted with (C_{1-8})alkyl, adamantyl or (C_{1-8})alkyl optionally mono- or, independently, pluri-substituted with hydroxy, hydroxymethyl or phenyl optionally mono- or, independently, di-substituted with lower alkyl, lower alkoxy or halogen;

h) a substituted adamantyl

in free form or in acid addition salt form;
and at least one further PPAR□ compound or the pharmaceutically acceptable salt of such a compound and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

Claim 3 (currently amended): The pharmaceutical composition according to claim ~~1~~ 2, wherein the further PPARα compound is selected from the group consisting of fenofibrate, micronized fenofibrate, bezafibrate, gemfibrazil and ciprofibrate or the pharmaceutically acceptable salt of such a compound.

Claim 4 (currently amended): The pharmaceutical composition according to claim ~~1~~ 2, which is a fixed combination.

Claim 5 (currently amended): The pharmaceutical composition according to claim ~~1~~ 2, which is a combined preparation.

Claim 6 (original): The pharmaceutical composition according to claim 5 which is a combined preparation for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by DPP-IV or PPARα.

Claim 7 (currently amended): The combination according to claim 1 ~~or a pharmaceutical composition according to any one of claims 2 to 6~~, wherein the DPP-IV inhibitor a compound of formula (I) which is selected from

(S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine; and

(S)-1-{2-[5-cyanopyridin-2-yl)amino]ethyl-aminoacetyl}-2-cyano-pyrrolidine;

in free form or in acid addition salt form.

Claim 8 (currently amended): The combination according to claim 1 ~~or a pharmaceutical composition according to any one of claims 2 to~~, wherein the DPP-IV inhibitor is selected from

(*S*)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine; and

(*S*)-1-{2-[5-cyanopyridin-2-yl)amino]ethyl-aminoacetyl}-2-cyano-pyrrolidine,

and the further PPARα compound is selected from the group consisting of fenofibrate, micronized fenofibrate, bezafibrate, gemfibrazil and ciprofibrate,

or the pharmaceutically acceptable salt of such a compound.

Claim 9 (original): A method of treating a condition mediated by DPP-IV or PPARα comprising administering to a warm-blooded animal in need thereof jointly therapeutically effective amounts of a DPP-IV inhibitor as defined in claim 1, in free or pharmaceutically acceptable salt form and at least one PPARα compound, or the pharmaceutically acceptable salts of such compounds.

Claim 10 (original): The method of claim 9, wherein the condition is dyslipidemia or obesity.

Claim 11 (original): The method of claim 9, wherein the condition is diabetes preferably type II diabetes.

Claim 12 (cancel):

Claim 13 (cancel):

Claim 14 (cancel):

Claim 15 (cancel):

Claim 16 (currently amended): ~~Use according to any one of claims 13 to 15~~ The method of claim 9, wherein the condition mediated by DPP-IV or PPARα, is selected from diabetes, type 2 diabetes mellitus, conditions of IGT, conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity, dyslipidemia and osteoporosis

Claim 17 (currently amended): ~~Use according to any one of claims 13 to 15~~ The method of claim 9, wherein the condition mediated by DPP-IV or PPARα, is selected from type 2 diabetes, impaired glucose tolerance, obesity and dyslipidemia.

Claim 18 (original): A commercial package comprising as active agents a combination of a DPP-IV inhibitor and a PPARα compound together with instructions for simultaneous, separate or

sequential use thereof in the prevention, delay of progression or treatment of a condition mediated by DPP-IV or PPARα.

Claim 19 (original): A kit of parts comprising

(a) an amount of a DPP IV inhibitor as defined in claim 1 or a pharmaceutically acceptable salt thereof in a first unit dosage form;

(b) an amount of at least one PPARα compound or the pharmaceutically acceptable salt thereof ,

in the form of two or three or more separate units of the components (a) and (b).

Claim 20 (original): A kit of parts according to claim 19 or a commercial package according to claim 18, wherein the DPP-IV inhibitor is selected from

(*S*)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine; and

(*S*)-1-{2-[5-cyanopyridin-2-yl)amino]ethyl-aminoacetyl}-2-cyano-pyrrolidine,

and the further PPARα compound is selected from the group consisting of fenofibrate, micronized fenofibrate, bezafibrate, gemfibrazil and ciprofibrate.